Biomarin Pharmaceutical (WBO:BMRN) PB Ratio

: 3.54 (As of Today)

View and export this data going back to 2017. Start your Free Trial

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-19), Biomarin Pharmaceutical's share price is €85.34. Biomarin Pharmaceutical's Book Value per Share for the quarter that ended in Dec. 2023 was €24.08. Hence, Biomarin Pharmaceutical's PB Ratio of today is 3.54.

The historical rank and industry rank for Biomarin Pharmaceutical's PB Ratio or its related term are showing as below:

WBO:BMRN' s PB Ratio Range Over the Past 10 Years
Min: 3.06 Med: 5.41 Max: 12.57
Current: 3.43

During the past 13 years, Biomarin Pharmaceutical's highest PB Ratio was 12.57. The lowest was 3.06. And the median was 5.41.

WBO:BMRN's PB Ratio is ranked worse than
64.79% of 1312 companies
in the Biotechnology industry
Industry Median: 2.385 vs WBO:BMRN: 3.43

During the past 12 months, Biomarin Pharmaceutical's average Book Value Per Share Growth Rate was 6.20% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 5.10% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 10.10% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 10.30% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Biomarin Pharmaceutical was 53.30% per year. The lowest was -13.40% per year. And the median was 13.00% per year.

Back to Basics: PB Ratio

Biomarin Pharmaceutical PB Ratio Historical Data

The historical data trend for Biomarin Pharmaceutical's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

PB Ratio

4.90

3.77

3.83

4.09

3.65

Biomarin Pharmaceutical Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
PB Ratio																4.09	3.83	3.44	3.45	3.65

Competitive Comparison

For the Biotechnology subindustry, Biomarin Pharmaceutical's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biomarin Pharmaceutical PB Ratio Distribution

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's PB Ratio distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's PB Ratio falls into.

Biomarin Pharmaceutical PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Biomarin Pharmaceutical's PB Ratio for today is calculated as follows:

PB Ratio	=	Share Price	/	Book Value per Share (Q: Dec. 2023)
	=	85.34	/	24.075
	=	3.54

It can also be calculated from the numbers for the whole company:

PB Ratio

Market Cap

(Total Stockholders Equity

Preferred Stock)

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Biomarin Pharmaceutical (WBO:BMRN) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.

Biomarin Pharmaceutical PB Ratio Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomarin Pharmaceutical (WBO:BMRN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (WBO:BMRN) » Definitions » PB Ratio

Comparable Companies

Traded in Other Exchanges

BMRN:USA 1BMRN:Italy BM8:Germany B1MR34:Brazil

Address

770 Lindaro Street, San Rafael, CA, USA, 94901

Website

http://www.bmrn.com

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.